← All trials
NCT06890039
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2025
- Primary completion
- Feb 28, 2026
- Completion date
- Dec 31, 2026
- First posted
- Mar 21, 2025
- Last posted
- Jul 29, 2025
- Enrollment
- 78
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yaqrit LtdLead sponsor
- Humboldt UniversityCollaborator
- University of LondonCollaborator
- European Foundation for Study of Chronic Liver FailureCollaborator
- Leiden UniversityCollaborator
- University of LeipzigCollaborator
- Assistance Publique - Hôpitaux de ParisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.